La Merie Publishing, Aug 2011, Pages: 91
CompetitorAnalysis: TargetedTherapy of HepatitisC The present Competitive Intelligence Report about TargetedTherapy of HepatitisC provides a competitor evaluation in the field of specifically
GBI Research, Jan 2011, Pages: 296
Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and HepatitisC Markets Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies
GlobalData, Oct 2011, Pages: 25
Details
Claros System - HepatitisC
Product Status
Product Description
Product Patent Details
Claros System - HIV
Product Status
Product Description
Product Patent Details
Claros System
La Merie Publishing, Sep 2008, Pages: 30
CompetitorAnalysis: HDL Raising Therapies The Competitive Intelligence Report HDL Raising Therapies as of September 2008 provides a competitoranalysis in the development pipeline of novel emerging
GlobalData, March 2012, Pages: 51
threatening ailments. The company offers INCIVEK (telaprevir), approved for the treatment of patients with genotype 1 hepatitisC virus (HCV) infection, and KALYDECO (ivacaftor), approved for the treatment
GlobalData, July 2011, Pages: 28
sources, put together with in-house analysis, by GlobalData's team of industry experts.
Scope
- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis
GlobalData, Sep 2011, Pages: 41
on the research and development of products for the antiviral and antibacterial markets. It is developing antivirals for the treatment of chronic hepatitisC and antibacterials for the treatment of resistant bacterial infections
GlobalData, March 2011, Pages: 19
products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development
GlobalData, Nov 2010, Pages: 19
. Pipeline Products by Therapy Area
eXagenBC(ER/PR+)
Product Status
Product Description
Pricing
eXaIBD
Product Status
Product Description
Product Milestone
HepatitisC Tests
Product Status
GlobalData, Nov 2010, Pages: 20
research and in-house analysis by Our team of industry experts.
Scope
- Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees
MP Advisors, Jan 2011, Pages: 391
analysis with explanations of how a drug will perform in its therapy area and how the market will shape up due to competition. Global Bio-Pharma Outlook 2011
India Pharma: Macro View
Para IV - The New
GlobalData, May 2011, Pages: 40
hepatitisC virus (HCV), hepatitis B virus (HBV) and human immunodeficiency virus (HIV). The company co-developed Tyzeka/Sebivo with Novartis AG for the treatment of chronic hepatitis B. Its pipeline products
GlobalData, Oct 2011, Pages: 18
or kidney transplantation field and liver regeneration; and AAV-Porphyria, a gene therapy for AIP to replenish PBGD levels.
This report is a source for data, analysis and actionable intelligence on the Digna
GlobalData, Sep 2011, Pages: 22
) is a biopharmaceutical company focused on commercializing therapeutic products for patients suffering with, Cardiovascular disease, Human Immunodeficiency Virus (HIV), HepatitisC, Cancer and Alzheimer's disease
GlobalData, Sep 2011, Pages: 21
. Aethlon Medical focuses on the treatment of cancer and chronic infectious diseases including Hepatitis-C and HIV, diseases caused by drug and vaccine resistant viruses. The company's wholly owned subsidiary
GlobalData, Feb 2012, Pages: 20
management models and reimbursement services. Operating through Therapeutic Resource Centers, the company provides targetedtherapy management programs to treat a broad range of medical conditions including
GlobalData, March 2012, Pages: 40
the patient's bloodstream. Its Phase III clinical trial product, the Delcath Percutaneous Hepatic Perfusion System (the Delcath PHP System), also known as as Hepatic Chemosaturation therapy allows physicians
